Glycolysis

Glucose G6P F6P F1,6BP GADP DHAP 1,3BPG 3PG 2PG PEP Pyruvate HK PGI PFK ALDO TPI GAPDH PGK PGM ENO PK Glycolysis The metabolic pathway of glycolysis converts glucose to pyruvate via a series of intermediate metabolites.    Each chemical modification is performed by a different enzyme.    Steps 1 and 3 consume ATP and    steps 7 and 10 produce ATP. Since steps 6–10 occur twice per glucose molecule, this leads to a net production of ATP.

Summary of aerobic respiration

Glycolysis is the metabolic pathway that converts glucose (C₆H₁₂O₆) into pyruvate and, in most organisms, occurs in the liquid part of cells (the cytosol). The free energy released in this process is used to form the high-energy molecules adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH). ^[1] Glycolysis is a sequence of ten reactions catalyzed by enzymes.

Summary of the 10 reactions of the glycolysis pathway

The wide occurrence of glycolysis in other species indicates that it is an ancient metabolic pathway. ^[2] Indeed, the reactions that make up glycolysis and its parallel pathway, the pentose phosphate pathway, can occur in the oxygen-free conditions of the Archean oceans, also in the absence of enzymes, catalyzed by metal ions, meaning this is a plausible prebiotic pathway for abiogenesis. ^[3]

The most common type of glycolysis is the Embden–Meyerhof–Parnas (EMP) pathway, which was discovered by Gustav Embden, Otto Meyerhof, and Jakub Karol Parnas. Glycolysis also refers to other pathways, such as the Entner–Doudoroff pathway and various heterofermentative and homofermentative pathways. However, the discussion here will be limited to the Embden–Meyerhof–Parnas pathway. ^[4]

The glycolysis pathway can be separated into two phases: ^[5]

1. Investment phase – wherein ATP is consumed
2. Yield phase – wherein more ATP is produced than originally consumed

Overview

The overall reaction of glycolysis is:

d-Glucose

 

+ 2 [NAD]⁺
+ 2 [ADP]
+ 2 [P]_i

 

2 × Pyruvate

2 × 

 

+ 2 [NADH]
+ 2 H⁺
+ 2 [ATP]
+ 2 H₂O

Glycolysis pathway overview

The use of symbols in this equation makes it appear unbalanced with respect to oxygen atoms, hydrogen atoms, and charges. Atom balance is maintained by the two phosphate (P_i) groups: ^[6]

• Each exists in the form of a hydrogen phosphate anion ([HPO₄]²⁻), dissociating to contribute 2H⁺ overall
• Each liberates an oxygen atom when it binds to an adenosine diphosphate (ADP) molecule, contributing 2 O overall

Charges are balanced by the difference between ADP and ATP. In the cellular environment, all three hydroxyl groups of ADP dissociate into −O⁻ and H⁺, giving ADP³⁻, and this ion tends to exist in an ionic bond with Mg²⁺, giving ADPMg⁻. ATP behaves identically except that it has four hydroxyl groups, giving ATPMg²⁻. When these differences along with the true charges on the two phosphate groups are considered together, the net charges of −4 on each side are balanced.^{[ citation needed ]}

In high-oxygen (aerobic) conditions, eukaryotic cells can continue from glycolysis to metabolise the pyruvate through the citric acid cycle or the electron transport chain to produce significantly more ATP.

Importantly, under low-oxygen (anaerobic) conditions, glycolysis is the only biochemical pathway in eukaryotes that can generate ATP, and, for many anaerobic respiring organisms the most important producer of ATP. ^[7] Therefore, many organisms have evolved fermentation pathways to recycle NAD⁺ to continue glycolysis to produce ATP for survival. These pathways include ethanol fermentation and lactic acid fermentation.

Metabolism of common monosaccharides, including glycolysis, gluconeogenesis, glycogenesis and glycogenolysis

History

The modern understanding of the pathway of glycolysis took almost 100 years to fully learn. ^[8] The combined results of many smaller experiments were required to understand the entire pathway.

The first steps in understanding glycolysis began in the 19th century. For economic reasons, the French wine industry sought to investigate why wine sometimes turned distasteful, instead of fermenting into alcohol. The French scientist Louis Pasteur researched this issue during the 1850s. ^[9] His experiments showed that alcohol fermentation occurs by the action of living microorganisms, yeasts, and that glucose consumption decreased under aerobic conditions (the Pasteur effect). ^[10]

Eduard Buchner discovered cell-free fermentation.

The component steps of glycolysis were first analysed by the non-cellular fermentation experiments of Eduard Buchner during the 1890s. ^{[11] [12]} Buchner demonstrated that the conversion of glucose to ethanol was possible using a non-living extract of yeast, due to the action of enzymes in the extract. ^{[13] : 135–148} This experiment not only revolutionized biochemistry, but also allowed later scientists to analyze this pathway in a more controlled laboratory setting. In a series of experiments (1905–1911), scientists Arthur Harden and William Young discovered more pieces of glycolysis. ^[14] They discovered the regulatory effects of ATP on glucose consumption during alcohol fermentation. They also shed light on the role of one compound as a glycolysis intermediate: fructose 1,6-bisphosphate. ^{[13] : 151–158}

The elucidation of fructose 1,6-bisphosphate was accomplished by measuring CO₂ levels when yeast juice was incubated with glucose. CO₂ production increased rapidly then slowed down. Harden and Young noted that this process would restart if an inorganic phosphate (Pi) was added to the mixture. Harden and Young deduced that this process produced organic phosphate esters, and further experiments allowed them to extract fructose diphosphate (F-1,6-DP).

Arthur Harden and William Young along with Nick Sheppard determined, in a second experiment, that a heat-sensitive high-molecular-weight subcellular fraction (the enzymes) and a heat-insensitive low-molecular-weight cytoplasm fraction (ADP, ATP and NAD⁺ and other cofactors) are required together for fermentation to proceed. This experiment begun by observing that dialyzed (purified) yeast juice could not ferment or even create a sugar phosphate. This mixture was rescued with the addition of undialyzed yeast extract that had been boiled. Boiling the yeast extract renders all proteins inactive (as it denatures them). The ability of boiled extract plus dialyzed juice to complete fermentation suggests that the cofactors were non-protein in character. ^[14]

Otto Meyerhof, one of the main scientists involved in completing the puzzle of glycolysis

In the 1920s Otto Meyerhof was able to link together some of the many individual pieces of glycolysis discovered by Buchner, Harden, and Young. Meyerhof and his team were able to extract different glycolytic enzymes from muscle tissue, and combine them to artificially create the pathway from glycogen to lactic acid. ^{[15] [16]}

In one paper, Meyerhof and scientist Renate Junowicz-Kockolaty investigated the reaction that splits fructose 1,6-diphosphate into the two triose phosphates. Previous work proposed that the split occurred via 1,3-diphosphoglyceraldehyde plus an oxidizing enzyme and cozymase. Meyerhoff and Junowicz found that the equilibrium constant for the isomerase and aldoses reaction were not affected by inorganic phosphates or any other cozymase or oxidizing enzymes. They further removed diphosphoglyceraldehyde as a possible intermediate in glycolysis. ^[16]

With all of these pieces available by the 1930s, Gustav Embden proposed a detailed, step-by-step outline of that pathway we now know as glycolysis. ^[17] The biggest difficulties in determining the intricacies of the pathway were due to the very short lifetime and low steady-state concentrations of the intermediates of the fast glycolytic reactions. By the 1940s, Meyerhof, Embden and many other biochemists had finally completed the puzzle of glycolysis. ^[16] The understanding of the isolated pathway has been expanded in the subsequent decades, to include further details of its regulation and integration with other metabolic pathways.

Sequence of reactions

Summary of reactions

Glucose

Hexokinase

ATP

ADP

Glucose 6-phosphate

Glucose-6-phosphate
isomerase

Fructose 6-phosphate

Phosphofructokinase-1

ATP

ADP

Fructose 1,6-bisphosphate

Fructose-bisphosphate
aldolase

Dihydroxyacetone phosphate

+

+

Glyceraldehyde 3-phosphate

Triosephosphate
isomerase

2 × Glyceraldehyde 3-phosphate

2 × 

Glyceraldehyde-3-phosphate
dehydrogenase

NAD⁺+ P_i

NADH + H⁺

NAD⁺+ P_i

NADH + H⁺

2 × 1,3-Bisphosphoglycerate

2 × 

Phosphoglycerate kinase

ADP

ATP

ADP

ATP

2 × 3-Phosphoglycerate

2 × 

Phosphoglycerate mutase

2 × 2-Phosphoglycerate

2 × 

Phosphopyruvate
hydratase (enolase)

 

H₂O

 

H₂O

2 × Phosphoenolpyruvate

2 × 

Pyruvate kinase

ADP

ATP

2 × Pyruvate

2 × 

Preparatory phase

The first five steps of Glycolysis are regarded as the preparatory (or investment) phase, since they consume energy to convert the glucose into two three-carbon sugar phosphates ^[5] (G3P).

d-Glucose (Glc)	Hexokinase glucokinase (HK) a transferase		α-d-Glucose-6-phosphate (G6P)
	ATP	H+ + ADP

Once glucose enters the cell, the first step is phosphorylation of glucose by a family of enzymes called hexokinases to form glucose 6-phosphate (G6P). This reaction consumes ATP, but it acts to keep the glucose concentration inside the cell low, promoting continuous transport of blood glucose into the cell through the plasma membrane transporters. In addition, phosphorylation blocks the glucose from leaking out – the cell lacks transporters for G6P, and free diffusion out of the cell is prevented due to the charged nature of G6P. Glucose may alternatively be formed from the phosphorolysis or hydrolysis of intracellular starch or glycogen.

In animals, an isozyme of hexokinase called glucokinase is also used in the liver, which has a much lower affinity for glucose (K_m in the vicinity of normal glycemia), and differs in regulatory properties. The different substrate affinity and alternate regulation of this enzyme are a reflection of the role of the liver in maintaining blood sugar levels.

Cofactors: Mg²⁺

---

α-d-Glucose 6-phosphate (G6P)	Phosphoglucoisomerase (PGI) an isomerase		β-d-Fructose 6-phosphate (F6P)

G6P is then rearranged into fructose 6-phosphate (F6P) by glucose phosphate isomerase. Fructose can also enter the glycolytic pathway by phosphorylation at this point.

The change in structure is an isomerization, in which the G6P has been converted to F6P. The reaction requires an enzyme, phosphoglucose isomerase, to proceed. This reaction is freely reversible under normal cell conditions. However, it is often driven forward because of a low concentration of F6P, which is constantly consumed during the next step of glycolysis. Under conditions of high F6P concentration, this reaction readily runs in reverse. This phenomenon can be explained through Le Chatelier's Principle. Isomerization to a keto sugar is necessary for carbanion stabilization in the fourth reaction step (below).

---

β-d-Fructose 6-phosphate (F6P)	Phosphofructokinase (PFK-1) a transferase		β-d-Fructose 1,6-bisphosphate (F1,6BP)
	ATP	H+ + ADP

The energy expenditure of another ATP in this step is justified in 2 ways: The glycolytic process (up to this step) becomes irreversible, and the energy supplied destabilizes the molecule. Because the reaction catalyzed by phosphofructokinase 1 (PFK-1) is coupled to the hydrolysis of ATP (an energetically favorable step) it is, in essence, irreversible, and a different pathway must be used to do the reverse conversion during gluconeogenesis. This makes the reaction a key regulatory point (see below).

Furthermore, the second phosphorylation event is necessary to allow the formation of two charged groups (rather than only one) in the subsequent step of glycolysis, ensuring the prevention of free diffusion of substrates out of the cell.

The same reaction can also be catalyzed by pyrophosphate-dependent phosphofructokinase (PFP or PPi-PFK), which is found in most plants, some bacteria, archea, and protists, but not in animals. This enzyme uses pyrophosphate (PPi) as a phosphate donor instead of ATP. It is a reversible reaction, increasing the flexibility of glycolytic metabolism. ^[18] A rarer ADP-dependent PFK enzyme variant has been identified in archaean species. ^[19]

Cofactors: Mg²⁺

---

β-d-Fructose 1,6-bisphosphate (F1,6BP)	Fructose-bisphosphate aldolase (ALDO) a lyase		d-Glyceraldehyde 3-phosphate (GADP)		Dihydroxyacetone phosphate (DHAP)
				+

Destabilizing the molecule in the previous reaction allows the hexose ring to be split by aldolase into two triose sugars: dihydroxyacetone phosphate (a ketose), and glyceraldehyde 3-phosphate (an aldose). There are two classes of aldolases: class I aldolases, present in animals and plants, and class II aldolases, present in fungi and bacteria; the two classes use different mechanisms in cleaving the ketose ring.

Electrons delocalized in the carbon-carbon bond cleavage associate with the alcohol group. The resulting carbanion is stabilized by the structure of the carbanion itself via resonance charge distribution and by the presence of a charged ion prosthetic group.

---

Dihydroxyacetone phosphate (DHAP)	Triosephosphate isomerase (TPI) an isomerase		d-Glyceraldehyde 3-phosphate (GADP)

Triosephosphate isomerase rapidly interconverts dihydroxyacetone phosphate with glyceraldehyde 3-phosphate (GADP) that proceeds further into glycolysis. This is advantageous, as it directs dihydroxyacetone phosphate down the same pathway as glyceraldehyde 3-phosphate, simplifying regulation.

Pay-off phase

The second half of glycolysis is known as the pay-off phase, characterised by a net gain of the energy-rich molecules ATP and NADH. ^[5] Since glucose leads to two triose sugars in the preparatory phase, each reaction in the pay-off phase occurs twice per glucose molecule. This yields 2 NADH molecules and 4 ATP molecules, leading to a net gain of 2 NADH molecules and 2 ATP molecules from the glycolytic pathway per glucose.

Glyceraldehyde 3-phosphate (GADP)	Glyceraldehyde phosphate dehydrogenase (GAPDH) an oxidoreductase		d-1,3-Bisphosphoglycerate (1,3BPG)
	NAD++ Pi	NADH + H+

The aldehyde groups of the triose sugars are oxidised, and inorganic phosphate is added to them, forming 1,3-bisphosphoglycerate.

The hydrogen is used to reduce two molecules of NAD⁺, a hydrogen carrier, to give NADH + H⁺ for each triose.

Hydrogen atom balance and charge balance are both maintained because the phosphate (P_i) group actually exists in the form of a hydrogen phosphate anion (HPO2−4), ^[6] which dissociates to contribute the extra H⁺ ion and gives a net charge of -3 on both sides.

Here, arsenate ([AsO₄]³⁻), an anion akin to inorganic phosphate may replace phosphate as a substrate to form 1-arseno-3-phosphoglycerate. This, however, is unstable and readily hydrolyzes to form 3-phosphoglycerate, the intermediate in the next step of the pathway. As a consequence of bypassing this step, the molecule of ATP generated from 1-3 bisphosphoglycerate in the next reaction will not be made, even though the reaction proceeds. As a result, arsenate is an uncoupler of glycolysis. ^[20]

---

1,3-Bisphosphoglycerate (1,3BPG)	Phosphoglycerate kinase (PGK) a transferase		3-Phosphoglycerate (3PG)
	ADP + H+	ATP
	Phosphoglycerate kinase (PGK)

This step is the enzymatic transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP by phosphoglycerate kinase, forming ATP and 3-phosphoglycerate. At this step, glycolysis has reached the break-even point: 2 molecules of ATP were consumed, and 2 new molecules have now been synthesized. This step, one of the two substrate-level phosphorylation steps, requires ADP; thus, when the cell has plenty of ATP (and little ADP), this reaction does not occur. Because ATP decays relatively quickly when it is not metabolized, this is an important regulatory point in the glycolytic pathway.

ADP actually exists as ADPMg⁻, and ATP as ATPMg²⁻, balancing the charges at −5 both sides.

Cofactors: Mg²⁺

---

3-Phosphoglycerate (3PG)	Phosphoglycerate mutase (PGM) a mutase		2-Phosphoglycerate (2PG)

Phosphoglycerate mutase isomerises 3-phosphoglycerate into 2-phosphoglycerate.

---

2-Phosphoglycerate (2PG)	Enolase (ENO) a lyase		Phosphoenolpyruvate (PEP)
		H2O
	Enolase (ENO)

Enolase next converts 2-phosphoglycerate to phosphoenolpyruvate. This reaction is an elimination reaction involving an E1cB mechanism.

Cofactors: 2 Mg²⁺, one "conformational" ion to coordinate with the carboxylate group of the substrate, and one "catalytic" ion that participates in the dehydration.

---

Phosphoenolpyruvate (PEP)	Pyruvate kinase (PK) a transferase		Pyruvate (Pyr)
	ADP + H+	ATP

A final substrate-level phosphorylation now forms a molecule of pyruvate and a molecule of ATP by means of the enzyme pyruvate kinase. This serves as an additional regulatory step, similar to the phosphoglycerate kinase step.

Cofactors: Mg²⁺

Biochemical logic

The existence of more than one point of regulation indicates that intermediates between those points enter and leave the glycolysis pathway by other processes. For example, in the first regulated step, hexokinase converts glucose into glucose-6-phosphate. Instead of continuing through the glycolysis pathway, this intermediate can be converted into glucose storage molecules, such as glycogen or starch. The reverse reaction, breaking down, e.g., glycogen, produces mainly glucose-6-phosphate; very little free glucose is formed in the reaction. The glucose-6-phosphate so produced can enter glycolysis after the first control point.

In the second regulated step (the third step of glycolysis), phosphofructokinase converts fructose-6-phosphate into fructose-1,6-bisphosphate, which then is converted into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. The dihydroxyacetone phosphate can be removed from glycolysis by conversion into glycerol-3-phosphate, which can be used to form triglycerides. ^[21] Conversely, triglycerides can be broken down into fatty acids and glycerol; the latter, in turn, can be converted into dihydroxyacetone phosphate, which can enter glycolysis after the second control point.

Free energy changes

Concentrations of metabolites in erythrocytes ^{[22] : 584}

Compound	Concentration / mM
Glucose	5.0
Glucose-6-phosphate	0.083
Fructose-6-phosphate	0.014
Fructose-1,6-bisphosphate	0.031
Dihydroxyacetone phosphate	0.14
Glyceraldehyde-3-phosphate	0.019
1,3-Bisphosphoglycerate	0.001
2,3-Bisphosphoglycerate	4.0
3-Phosphoglycerate	0.12
2-Phosphoglycerate	0.03
Phosphoenolpyruvate	0.023
Pyruvate	0.051
ATP	1.85
ADP	0.14
Pi	1.0

The change in free energy, ΔG, for each step in the glycolysis pathway can be calculated using ΔG = ΔG°′ + RTln Q, where Q is the reaction quotient. This requires knowing the concentrations of the metabolites. All of these values are available for erythrocytes, with the exception of the concentrations of NAD⁺ and NADH. The ratio of NAD⁺ to NADH in the cytoplasm is approximately 1000, which makes the oxidation of glyceraldehyde-3-phosphate (step 6) more favourable.

Using the measured concentrations of each step, and the standard free energy changes, the actual free energy change can be calculated. (Neglecting this is very common—the delta G of ATP hydrolysis in cells is not the standard free energy change of ATP hydrolysis quoted in textbooks).

Change in free energy for each step of glycolysis ^{[22] : 582–583}

Step	Reaction	ΔG°′ (kJ/mol)		ΔG (kJ/mol)
1	Glucose + ATP4− → Glucose-6-phosphate2− + ADP3− + H+	−16	.7	−34
2	Glucose-6-phosphate2− → Fructose-6-phosphate2−	1	.67	−2	.9
3	Fructose-6-phosphate2− + ATP4− → Fructose-1,6-bisphosphate4− + ADP3− + H+	−14	.2	−19
4	Fructose-1,6-bisphosphate4− → Dihydroxyacetone phosphate2− + Glyceraldehyde-3-phosphate2−	23	.9	−0	.23
5	Dihydroxyacetone phosphate2− → Glyceraldehyde-3-phosphate2−	7	.56	2	.4
6	Glyceraldehyde-3-phosphate2− + Pi2− + NAD+ → 1,3-Bisphosphoglycerate4− + NADH + H+	6	.30	−1	.29
7	1,3-Bisphosphoglycerate4− + ADP3− → 3-Phosphoglycerate3− + ATP4−	−18	.9	0	.09
8	3-Phosphoglycerate3− → 2-Phosphoglycerate3−	4	.4	0	.83
9	2-Phosphoglycerate3− → Phosphoenolpyruvate3− + H2O	1	.8	1	.1
10	Phosphoenolpyruvate3− + ADP3− + H+ → Pyruvate− + ATP4−	−31	.7	−23	.0

From measuring the physiological concentrations of metabolites in an erythrocyte it seems that about seven of the steps in glycolysis are in equilibrium for that cell type. Three of the steps—the ones with large negative free energy changes—are not in equilibrium and are referred to as irreversible; such steps are often subject to regulation.

Step 5 in the figure is shown behind the other steps, because that step is a side-reaction that can decrease or increase the concentration of the intermediate glyceraldehyde-3-phosphate. That compound is converted to dihydroxyacetone phosphate by the enzyme triose phosphate isomerase, which is a catalytically perfect enzyme; its rate is so fast that the reaction can be assumed to be in equilibrium. The fact that ΔG is not zero indicates that the actual concentrations in the erythrocyte are not accurately known.

Regulation

The enzymes that catalyse glycolysis are regulated via a range of biological mechanisms in order to control overall flux though the pathway. This is vital for both homeostatsis in a static environment, and metabolic adaptation to a changing environment or need. ^[23] The details of regulation for some enzymes are highly conserved between species, whereas others vary widely. ^{[24] [25]}

1. Gene Expression: Firstly, the cellular concentrations of glycolytic enzymes are modulated via regulation of gene expression via transcription factors, ^[26] with several glycolysis enzymes themselves acting as regulatory protein kinases in the nucleus. ^[27]
2. Allosteric inhibition and activation by metabolites: In particular end-product inhibition of regulated enzymes by metabolites such as ATP serves as negative feedback regulation of the pathway. ^{[24] [28]}
3. Allosteric inhibition and activation by Protein-protein interactions (PPI). ^[29] Indeed, some proteins interact with and regulate multiple glycolytic enzymes. ^[30]
4. Post-translational modification (PTM). ^[31] In particular, phosphorylation and dephosphorylation is a key mechanism of regulation of pyruvate kinase in the liver.
5. Localization ^[28]

Regulation by insulin in animals

In animals, regulation of blood glucose levels by the pancreas in conjunction with the liver is a vital part of homeostasis. The beta cells in the pancreatic islets are sensitive to the blood glucose concentration. ^[32] A rise in the blood glucose concentration causes them to release insulin into the blood, which has an effect particularly on the liver, but also on fat and muscle cells, causing these tissues to remove glucose from the blood. When the blood sugar falls the pancreatic beta cells cease insulin production, but, instead, stimulate the neighboring pancreatic alpha cells to release glucagon into the blood. ^[32] This, in turn, causes the liver to release glucose into the blood by breaking down stored glycogen, and by means of gluconeogenesis. If the fall in the blood glucose level is particularly rapid or severe, other glucose sensors cause the release of epinephrine from the adrenal glands into the blood. This has the same action as glucagon on glucose metabolism, but its effect is more pronounced. ^[32] In the liver glucagon and epinephrine cause the phosphorylation of the key, regulated enzymes of glycolysis, fatty acid synthesis, cholesterol synthesis, gluconeogenesis, and glycogenolysis. Insulin has the opposite effect on these enzymes. ^[33] The phosphorylation and dephosphorylation of these enzymes (ultimately in response to the glucose level in the blood) is the dominant manner by which these pathways are controlled in the liver, fat, and muscle cells. Thus the phosphorylation of phosphofructokinase inhibits glycolysis, whereas its dephosphorylation through the action of insulin stimulates glycolysis. ^[33]

Regulated Enzymes in Glycolysis

The three regulatory enzymes are hexokinase (or glucokinase in the liver), phosphofructokinase, and pyruvate kinase. The flux through the glycolytic pathway is adjusted in response to conditions both inside and outside the cell. The internal factors that regulate glycolysis do so primarily to provide ATP in adequate quantities for the cell's needs. The external factors act primarily on the liver, fat tissue, and muscles, which can remove large quantities of glucose from the blood after meals (thus preventing hyperglycemia by storing the excess glucose as fat or glycogen, depending on the tissue type). The liver is also capable of releasing glucose into the blood between meals, during fasting, and exercise thus preventing hypoglycemia by means of glycogenolysis and gluconeogenesis. These latter reactions coincide with the halting of glycolysis in the liver.

In addition hexokinase and glucokinase act independently of the hormonal effects as controls at the entry points of glucose into the cells of different tissues. Hexokinase responds to the glucose-6-phosphate (G6P) level in the cell, or, in the case of glucokinase, to the blood sugar level in the blood to impart entirely intracellular controls of the glycolytic pathway in different tissues (see below). ^[33]

When glucose has been converted into G6P by hexokinase or glucokinase, it can either be converted to glucose-1-phosphate (G1P) for conversion to glycogen, or it is alternatively converted by glycolysis to pyruvate, which enters the mitochondrion where it is converted into acetyl-CoA and then into citrate. Excess citrate is exported from the mitochondrion back into the cytosol, where ATP citrate lyase regenerates acetyl-CoA and oxaloacetate (OAA). The acetyl-CoA is then used for fatty acid synthesis and cholesterol synthesis, two important ways of utilizing excess glucose when its concentration is high in blood. The regulated enzymes catalyzing these reactions perform these functions when they have been dephosphorylated through the action of insulin on the liver cells. Between meals, during fasting, exercise or hypoglycemia, glucagon and epinephrine are released into the blood. This causes liver glycogen to be converted back to G6P, and then converted to glucose by the liver-specific enzyme glucose 6-phosphatase and released into the blood. Glucagon and epinephrine also stimulate gluconeogenesis, which converts non-carbohydrate substrates into G6P, which joins the G6P derived from glycogen, or substitutes for it when the liver glycogen store have been depleted. This is critical for brain function, since the brain utilizes glucose as an energy source under most conditions. ^[34] The simultaneously phosphorylation of, particularly, phosphofructokinase, but also, to a certain extent pyruvate kinase, prevents glycolysis occurring at the same time as gluconeogenesis and glycogenolysis.

Hexokinase and glucokinase

Yeast hexokinase B ( PDB: 1IG8 ​)

All cells contain the enzyme hexokinase, which catalyzes the conversion of glucose that has entered the cell into glucose-6-phosphate (G6P). Since the cell membrane is impervious to G6P, hexokinase essentially acts to transport glucose into the cells from which it can then no longer escape. Hexokinase is inhibited by high levels of G6P in the cell. Thus the rate of entry of glucose into cells partially depends on how fast G6P can be disposed of by glycolysis, and by glycogen synthesis (in the cells which store glycogen, namely liver and muscles). ^{[33] [35]}

Glucokinase, unlike hexokinase, is not inhibited by G6P. It occurs in liver cells, and will only phosphorylate the glucose entering the cell to form G6P, when the glucose in the blood is abundant. This being the first step in the glycolytic pathway in the liver, it therefore imparts an additional layer of control of the glycolytic pathway in this organ. ^[33]

Phosphofructokinase

Bacillus stearothermophilus phosphofructokinase ( PDB: 6PFK ​)

Phosphofructokinase is an important control point in the glycolytic pathway, since it is one of the irreversible steps and has key allosteric effectors, AMP and fructose 2,6-bisphosphate (F2,6BP).

F2,6BP is a very potent activator of phosphofructokinase (PFK-1) that is synthesized when F6P is phosphorylated by a second phosphofructokinase (PFK2). In the liver, when blood sugar is low and glucagon elevates cAMP, PFK2 is phosphorylated by protein kinase A. The phosphorylation inactivates PFK2, and another domain on this protein becomes active as fructose bisphosphatase-2, which converts F2,6BP back to F6P. Both glucagon and epinephrine cause high levels of cAMP in the liver. The result of lower levels of liver F2,6BP is a decrease in activity of phosphofructokinase and an increase in activity of fructose 1,6-bisphosphatase, so that gluconeogenesis (in essence, "glycolysis in reverse") is favored. This is consistent with the role of the liver in such situations, since the response of the liver to these hormones is to release glucose to the blood.

ATP competes with AMP for the allosteric effector site on the PFK enzyme. ATP concentrations in cells are much higher than those of AMP, typically 100-fold higher, ^[36] but the concentration of ATP does not change more than about 10% under physiological conditions, whereas a 10% drop in ATP results in a 6-fold increase in AMP. ^[37] Thus, the relevance of ATP as an allosteric effector is questionable. An increase in AMP is a consequence of a decrease in energy charge in the cell.

Citrate inhibits phosphofructokinase when tested in vitro by enhancing the inhibitory effect of ATP. However, it is doubtful that this is a meaningful effect in vivo, because citrate in the cytosol is utilized mainly for conversion to acetyl-CoA for fatty acid and cholesterol synthesis.

TIGAR, a p53 induced enzyme, is responsible for the regulation of phosphofructokinase and acts to protect against oxidative stress. ^[38] TIGAR is a single enzyme with dual function that regulates F2,6BP. It can behave as a phosphatase (fructuose-2,6-bisphosphatase) which cleaves the phosphate at carbon-2 producing F6P. It can also behave as a kinase (PFK2) adding a phosphate onto carbon-2 of F6P which produces F2,6BP. In humans, the TIGAR protein is encoded by C12orf5 gene. The TIGAR enzyme will hinder the forward progression of glycolysis, by creating a build up of fructose-6-phosphate (F6P) which is isomerized into glucose-6-phosphate (G6P). The accumulation of G6P will shunt carbons into the pentose phosphate pathway. ^{[39] [40]}

Pyruvate kinase

Yeast pyruvate kinase ( PDB: 1A3W ​)

Main article: Pyruvate kinase

The final step of glycolysis is catalysed by pyruvate kinase to form pyruvate and another ATP. It is regulated by a range of different transcriptional, covalent and non-covalent regulation mechanisms, which can vary widely in different tissues. ^{[41] [42] [43]} For example, in the liver, pyruvate kinase is regulated based on glucose availability. During fasting (no glucose available), glucagon activates protein kinase A which phosphorylates pyruvate kinase to inhibit it. ^[44] An increase in blood sugar leads to secretion of insulin, which activates protein phosphatase 1, leading to dephosphorylation and re-activation of pyruvate kinase. ^[44] These controls prevent pyruvate kinase from being active at the same time as the enzymes that catalyze the reverse reaction (pyruvate carboxylase and phosphoenolpyruvate carboxykinase), preventing a futile cycle. ^[44] Conversely, the isoform of pyruvate kinasein found in muscle is not affected by protein kinase A (which is activated by adrenaline in that tissue), so that glycolysis remains active in muscles even during fasting. ^[44]

Post-glycolysis processes

The overall process of glycolysis is:

Glucose + 2 NAD⁺ + 2 ADP + 2 P_i → 2 Pyruvate + 2 NADH + 2 H⁺ + 2 ATP + 2 H₂O

If glycolysis were to continue indefinitely, all of the NAD⁺ would be used up, and glycolysis would stop. To allow glycolysis to continue, organisms must be able to oxidize NADH back to NAD⁺. How this is performed depends on which external electron acceptor is available.

Anoxic regeneration of NAD⁺

One method of doing this is to simply have the pyruvate do the oxidation; in this process, pyruvate is converted to lactate (the conjugate base of lactic acid) in a process called lactic acid fermentation:

Pyruvate + NADH + H⁺ → Lactate + NAD⁺

This process occurs in the bacteria involved in making yogurt (the lactic acid causes the milk to curdle). This process also occurs in animals under hypoxic (or partially anaerobic) conditions, found, for example, in overworked muscles that are starved of oxygen. In many tissues, this is a cellular last resort for energy; most animal tissue cannot tolerate anaerobic conditions for an extended period of time.

Some organisms, such as yeast, convert NADH back to NAD⁺ in a process called ethanol fermentation. In this process, the pyruvate is converted first to acetaldehyde and carbon dioxide, and then to ethanol.

Lactic acid fermentation and ethanol fermentation can occur in the absence of oxygen. This anaerobic fermentation allows many single-cell organisms to use glycolysis as their only energy source.

Anoxic regeneration of NAD⁺ is only an effective means of energy production during short, intense exercise in vertebrates, for a period ranging from 10 seconds to 2 minutes during a maximal effort in humans. (At lower exercise intensities it can sustain muscle activity in diving animals, such as seals, whales and other aquatic vertebrates, for very much longer periods of time.) Under these conditions NAD⁺ is replenished by NADH donating its electrons to pyruvate to form lactate. This produces 2 ATP molecules per glucose molecule, or about 5% of glucose's energy potential (38 ATP molecules in bacteria). But the speed at which ATP is produced in this manner is about 100 times that of oxidative phosphorylation. The pH in the cytoplasm quickly drops when hydrogen ions accumulate in the muscle, eventually inhibiting the enzymes involved in glycolysis.

The burning sensation in muscles during hard exercise can be attributed to the release of hydrogen ions during the shift to glucose fermentation from glucose oxidation to carbon dioxide and water, when aerobic metabolism can no longer keep pace with the energy demands of the muscles. These hydrogen ions form a part of lactic acid. The body falls back on this less efficient but faster method of producing ATP under low oxygen conditions. This is thought to have been the primary means of energy production in earlier organisms before oxygen reached high concentrations in the atmosphere between 2000 and 2500 million years ago, and thus would represent a more ancient form of energy production than the aerobic replenishment of NAD⁺ in cells.

The liver in mammals gets rid of this excess lactate by transforming it back into pyruvate under aerobic conditions; see Cori cycle.

Fermentation of pyruvate to lactate is sometimes also called "anaerobic glycolysis", however, glycolysis ends with the production of pyruvate regardless of the presence or absence of oxygen.

In the above two examples of fermentation, NADH is oxidized by transferring two electrons to pyruvate. However, anaerobic bacteria use a wide variety of compounds as the terminal electron acceptors in cellular respiration: nitrogenous compounds, such as nitrates and nitrites; sulfur compounds, such as sulfates, sulfites, sulfur dioxide, and elemental sulfur; carbon dioxide; iron compounds; manganese compounds; cobalt compounds; and uranium compounds.

Aerobic regeneration of NAD⁺ and further catabolism of pyruvate

In aerobic eukaryotes, a complex mechanism has developed to use the oxygen in air as the final electron acceptor, in a process called oxidative phosphorylation. Aerobic prokaryotes, which lack mitochondria, use a variety of simpler mechanisms.

• Firstly, the NADH + H⁺ generated by glycolysis has to be transferred to the mitochondrion to be oxidized, and thus to regenerate the NAD⁺ necessary for glycolysis to continue. However the inner mitochondrial membrane is impermeable to NADH and NAD⁺. ^[45] Use is therefore made of two "shuttles" to transport the electrons from NADH across the mitochondrial membrane. They are the malate-aspartate shuttle and the glycerol phosphate shuttle. In the former the electrons from NADH are transferred to cytosolic oxaloacetate to form malate. The malate then traverses the inner mitochondrial membrane into the mitochondrial matrix, where it is reoxidized by NAD⁺ forming intra-mitochondrial oxaloacetate and NADH. The oxaloacetate is then re-cycled to the cytosol via its conversion to aspartate which is readily transported out of the mitochondrion. In the glycerol phosphate shuttle electrons from cytosolic NADH are transferred to dihydroxyacetone to form glycerol-3-phosphate which readily traverses the outer mitochondrial membrane. Glycerol-3-phosphate is then reoxidized to dihydroxyacetone, donating its electrons to FAD instead of NAD⁺. ^[45] This reaction takes place on the inner mitochondrial membrane, allowing FADH₂ to donate its electrons directly to coenzyme Q (ubiquinone) which is part of the electron transport chain which ultimately transfers electrons to molecular oxygen O₂, with the formation of water, and the release of energy eventually captured in the form of ATP.
• The glycolytic end-product, pyruvate (plus NAD⁺) is converted to acetyl-CoA, CO₂ and NADH + H⁺ within the mitochondria in a process called pyruvate decarboxylation.
• The resulting acetyl-CoA enters the citric acid cycle (or Krebs Cycle), where the acetyl group of the acetyl-CoA is converted into carbon dioxide by two decarboxylation reactions with the formation of yet more intra-mitochondrial NADH + H⁺.
• The intra-mitochondrial NADH + H⁺ is oxidized to NAD⁺ by the electron transport chain, using oxygen as the final electron acceptor to form water. The energy released during this process is used to create a hydrogen ion (or proton) gradient across the inner membrane of the mitochondrion.
• Finally, the proton gradient is used to produce about 2.5 ATP for every NADH + H⁺ oxidized in a process called oxidative phosphorylation. ^[45]

Conversion of carbohydrates into fatty acids and cholesterol

The pyruvate produced by glycolysis is an important intermediary in the conversion of carbohydrates into fatty acids and cholesterol. ^[46] This occurs via the conversion of pyruvate into acetyl-CoA in the mitochondrion. However, this acetyl CoA needs to be transported into cytosol where the synthesis of fatty acids and cholesterol occurs. This cannot occur directly. To obtain cytosolic acetyl-CoA, citrate (produced by the condensation of acetyl CoA with oxaloacetate) is removed from the citric acid cycle and carried across the inner mitochondrial membrane into the cytosol. ^[46] There it is cleaved by ATP citrate lyase into acetyl-CoA and oxaloacetate. The oxaloacetate is returned to mitochondrion as malate (and then back into oxaloacetate to transfer more acetyl-CoA out of the mitochondrion). The cytosolic acetyl-CoA can be carboxylated by acetyl-CoA carboxylase into malonyl CoA, the first committed step in the synthesis of fatty acids, or it can be combined with acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) which is the rate limiting step controlling the synthesis of cholesterol. ^[47] Cholesterol can be used as is, as a structural component of cellular membranes, or it can be used to synthesize the steroid hormones, bile salts, and vitamin D. ^{[35] [46] [47]}

Conversion of pyruvate into oxaloacetate for the citric acid cycle

Pyruvate molecules produced by glycolysis are actively transported across the inner mitochondrial membrane, and into the matrix where they can either be oxidized and combined with coenzyme A to form CO₂, acetyl-CoA, and NADH, ^[35] or they can be carboxylated (by pyruvate carboxylase) to form oxaloacetate. This latter reaction "fills up" the amount of oxaloacetate in the citric acid cycle, and is therefore an anaplerotic reaction (from the Greek meaning to "fill up"), increasing the cycle's capacity to metabolize acetyl-CoA when the tissue's energy needs (e.g. in heart and skeletal muscle) are suddenly increased by activity. ^[48] In the citric acid cycle all the intermediates (e.g. citrate, iso-citrate, alpha-ketoglutarate, succinate, fumarate, malate and oxaloacetate) are regenerated during each turn of the cycle. Adding more of any of these intermediates to the mitochondrion therefore means that that additional amount is retained within the cycle, increasing all the other intermediates as one is converted into the other. Hence the addition of oxaloacetate greatly increases the amounts of all the citric acid intermediates, thereby increasing the cycle's capacity to metabolize acetyl CoA, converting its acetate component into CO₂ and water, with the release of enough energy to form 11 ATP and 1 GTP molecule for each additional molecule of acetyl CoA that combines with oxaloacetate in the cycle. ^[48]

To cataplerotically remove oxaloacetate from the citric cycle, malate can be transported from the mitochondrion into the cytoplasm, decreasing the amount of oxaloacetate that can be regenerated. ^[48] Furthermore, citric acid intermediates are constantly used to form a variety of substances such as the purines, pyrimidines and porphyrins. ^[48]

Intermediates for other pathways

This article concentrates on the catabolic role of glycolysis with regard to converting potential chemical energy to usable chemical energy during the oxidation of glucose to pyruvate. Many of the metabolites in the glycolytic pathway are also used by anabolic pathways, and, as a consequence, flux through the pathway is critical to maintain a supply of carbon skeletons for biosynthesis. ^[49]

The following metabolic pathways are all strongly reliant on glycolysis as a source of metabolites: and many more.

• Pentose phosphate pathway, which begins with the dehydrogenation of glucose-6-phosphate, the first intermediate to be produced by glycolysis, produces various pentose sugars, and NADPH for the synthesis of fatty acids and cholesterol.
• Glycogen synthesis also starts with glucose-6-phosphate at the beginning of the glycolytic pathway.
• Glycerol, for the formation of triglycerides and phospholipids, is produced from the glycolytic intermediate glyceraldehyde-3-phosphate.
• Various post-glycolytic pathways:

• Fatty acid synthesis
• Cholesterol synthesis
• The citric acid cycle which in turn leads to:

• Amino acid synthesis
• Nucleotide synthesis
• Tetrapyrrole synthesis

Although gluconeogenesis and glycolysis share many intermediates the one is not functionally a branch or tributary of the other. There are two regulatory steps in both pathways which, when active in the one pathway, are automatically inactive in the other. The two processes can therefore not be simultaneously active. ^[50] Indeed, if both sets of reactions were highly active at the same time the net result would be the hydrolysis of four high energy phosphate bonds (two ATP and two GTP) per reaction cycle. ^[50]

NAD⁺ is the oxidizing agent in glycolysis, as it is in most other energy yielding metabolic reactions (e.g. beta-oxidation of fatty acids, and during the citric acid cycle). The NADH thus produced is primarily used to ultimately transfer electrons to O₂ to produce water, or, when O₂ is not available, to produce compounds such as lactate or ethanol (see Anoxic regeneration of NAD⁺ above). NADH is rarely used for synthetic processes, the notable exception being gluconeogenesis. During fatty acid and cholesterol synthesis the reducing agent is NADPH. This difference exemplifies a general principle that NADPH is consumed during biosynthetic reactions, whereas NADH is generated in energy-yielding reactions. ^[50] The source of the NADPH is two-fold. When malate is oxidatively decarboxylated by "NADP⁺-linked malic enzyme" pyruvate, CO₂ and NADPH are formed. NADPH is also formed by the pentose phosphate pathway which converts glucose into ribose, which can be used in synthesis of nucleotides and nucleic acids, or it can be catabolized to pyruvate. ^[50]

Glycolysis in disease

Diabetes

Cellular uptake of glucose occurs in response to insulin signals, and glucose is subsequently broken down through glycolysis, lowering blood sugar levels. However, insulin resistance or low insulin levels seen in diabetes result in hyperglycemia, where glucose levels in the blood rise and glucose is not properly taken up by cells. Hepatocytes further contribute to this hyperglycemia through gluconeogenesis. Glycolysis in hepatocytes controls hepatic glucose production, and when glucose is overproduced by the liver without having a means of being broken down by the body, hyperglycemia results. ^[51]

Genetic diseases

Glycolytic mutations are generally rare due to importance of the metabolic pathway; the majority of occurring mutations result in an inability of the cell to respire, and therefore cause the death of the cell at an early stage. However, some mutations (glycogen storage diseases and other inborn errors of carbohydrate metabolism) are seen with one notable example being pyruvate kinase deficiency, leading to chronic hemolytic anemia.^{[ citation needed ]}

In combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, glycolysis is reduced by -50%, which is caused by reduced lipoylation of mitochondrial enzymes such as the pyruvate dehydrogenase complex and α-ketoglutarate dehydrogenase complex. ^[52]

Cancer

Malignant tumor cells perform glycolysis at a rate that is ten times faster than their noncancerous tissue counterparts. ^[53] During their genesis, limited capillary support often results in hypoxia (decreased O2 supply) within the tumor cells. Thus, these cells rely on anaerobic metabolic processes such as glycolysis for ATP (adenosine triphosphate). Some tumor cells overexpress specific glycolytic enzymes which result in higher rates of glycolysis. ^[54] Often these enzymes are Isoenzymes, of traditional glycolysis enzymes, that vary in their susceptibility to traditional feedback inhibition. The increase in glycolytic activity ultimately counteracts the effects of hypoxia by generating sufficient ATP from this anaerobic pathway. ^[55] This phenomenon was first described in 1930 by Otto Warburg and is referred to as the Warburg effect. The Warburg hypothesis claims that cancer is primarily caused by dysfunctionality in mitochondrial metabolism, rather than because of the uncontrolled growth of cells. A number of theories have been advanced to explain the Warburg effect. One such theory suggests that the increased glycolysis is a normal protective process of the body and that malignant change could be primarily caused by energy metabolism. ^[56]

This high glycolysis rate has important medical applications, as high aerobic glycolysis by malignant tumors is utilized clinically to diagnose and monitor treatment responses of cancers by imaging uptake of 2-¹⁸F-2-deoxyglucose (FDG) (a radioactive modified hexokinase substrate) with positron emission tomography (PET). ^{[57] [58]}

There is ongoing research to affect mitochondrial metabolism and treat cancer by reducing glycolysis and thus starving cancerous cells in various new ways, including a ketogenic diet. ^{[59] [60] [61]}

Interactive pathway map

The diagram below shows human protein names. Names in other organisms may be different and the number of isozymes (such as HK1, HK2, ...) is likely to be different too.

Click on genes, proteins and metabolites below to link to respective articles. ^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|alt=Glycolysis and Gluconeogenesis edit]]

Glycolysis and Gluconeogenesis edit

1. The interactive pathway map can be edited at WikiPathways: "GlycolysisGluconeogenesis_WP534".

Alternative nomenclature

Some of the metabolites in glycolysis have alternative names and nomenclature. In part, this is because some of them are common to other pathways, such as the Calvin cycle.

	This article		Alternative
1	Glucose	Glc	Dextrose
2	Glucose-6-phosphate	G6P
3	Fructose-6-phosphate	F6P
4	Fructose-1,6-bisphosphate	F1,6BP	Fructose 1,6-diphosphate	FBP; FDP; F1,6DP
5	Dihydroxyacetone phosphate	DHAP	Glycerone phosphate
6	Glyceraldehyde-3-phosphate	GADP	3-Phosphoglyceraldehyde	PGAL; G3P; GALP; GAP; TP
7	1,3-Bisphosphoglycerate	1,3BPG	Glycerate-1,3-bisphosphate, glycerate-1,3-diphosphate, 1,3-diphosphoglycerate	PGAP; BPG; DPG
8	3-Phosphoglycerate	3PG	Glycerate-3-phosphate	PGA; GP
9	2-Phosphoglycerate	2PG	Glycerate-2-phosphate
10	Phosphoenolpyruvate	PEP
11	Pyruvate	Pyr	Pyruvic acid conjugate base

Structure of glycolysis components in Fischer projections and polygonal model

The intermediates of glycolysis depicted in Fischer projections show the chemical changing step by step. Such image can be compared to polygonal model representation. ^[62]

Glycolysis - Structure of anaerobic glycolysis components showed using Fischer projections, left, and polygonal model, right. The compounds correspond to glucose (GLU), glucose 6-phosphate (G6P), fructose 6-phosphate (F6P), fructose 1,6-bisphosphate ( F16BP), dihydroxyacetone phosphate (DHAP), glyceraldehyde 3-phosphate(GA3P), 1,3-bisphosphoglycerate (13BPG), 3-phosphoglycerate (3PG), 2-phosphoglycerate (2PG), phosphoenolpyruvate (PEP), pyruvate (PIR), and lactate (LAC). The enzymes which participate of this pathway are indicated by underlined numbers, and correspond to hexokinase (1), glucose-6-phosphate isomerase (2), phosphofructokinase-1 (3), fructose-bisphosphate aldolase (4), triosephosphate isomerase (5), glyceraldehyde-3-phosphate dehydrogenase (5), phosphoglycerate kinase (7), phosphoglycerate mutase (8), phosphopyruvate hydratase (enolase) (9), pyruvate kinase (10), and lactate dehydrogenase (11). The participant coenzymes (NAD⁺, NADH + H⁺, ATP and ADP), inorganic phosphate, H₂O and CO₂ were omitted in these representations. The phosphorylation reactions from ATP, as well the ADP phosphorylation reactions in later steps of glycolysis are shown as ~P respectively entering or going out the pathway. The oxireduction reactions using NAD⁺ or NADH are observed as hydrogens "2H" going out or entering the pathway.

See also

• Biology portal

• Carbohydrate catabolism
• Citric acid cycle
• Cori cycle
• Fermentation (biochemistry)
• Gluconeogenesis
• Glycolytic oscillation
• Glycogenoses (glycogen storage diseases)
• Inborn errors of carbohydrate metabolism
• Pentose phosphate pathway
• Pyruvate decarboxylation
• Triose kinase

References

1. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, et al. (18 December 2014). "Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question". Oncoscience. 1 (12): 777–802. doi:10.18632/oncoscience.109. PMC   4303887 . PMID   25621294.
2. Romano AH, Conway T (1996). "Evolution of carbohydrate metabolic pathways". Research in Microbiology. 147 (6–7): 448–455. doi: 10.1016/0923-2508(96)83998-2 . PMID   9084754.
3. Keller MA, Turchyn AV, Ralser M (April 2014). "Non-enzymatic glycolysis and pentose phosphate pathway-like reactions in a plausible Archean ocean". Molecular Systems Biology. 10 (4): 725. doi:10.1002/msb.20145228. PMC   4023395 . PMID   24771084.
4. Kim BH, Gadd GM. (2011) Bacterial Physiology and Metabolism, 3rd edition.
5. Mehta S (20 September 2011). "Glycolysis – Animation and Notes". PharmaXchange. Archived from the original on 25 March 2012. Retrieved 22 September 2011.
6. Lane AN, Fan TW, Higashi RM (2009). "Metabolic acidosis and the importance of balanced equations". Metabolomics. 5 (2): 163–165. doi:10.1007/s11306-008-0142-2. S2CID   35500999.
7. Molecular Biology of the Cell (6th ed.). Garland Science. 18 November 2014. p. 75. ISBN   978-0815344322.
8. Barnett JA (April 2003). "A history of research on yeasts 5: the fermentation pathway". Yeast. 20 (6): 509–543. doi: 10.1002/yea.986 . PMID   12722184. S2CID   26805351.
9. "Louis Pasteur and Alcoholic Fermentation". www.pasteurbrewing.com. Archived from the original on 2011-01-13. Retrieved 2016-02-23.
10. Alba-Lois L, Segal-Kischinevzky C (January 2010). "Yeast fermentation and the making of beer and wine". Nature Education. 3 (9): 17.
11. Kohler R (1971-03-01). "The background to Eduard Buchner's discovery of cell-free fermentation". Journal of the History of Biology. 4 (1): 35–61. doi:10.1007/BF00356976. PMID   11609437. S2CID   46573308.
12. "Eduard Buchner - Biographical". www.nobelprize.org. Retrieved 2016-02-23.
13. Cornish-Bawden A, ed. (1997). "Harden and Young's Discovery of Fructose 1,6-Bisphosphate". New Beer in an Old Bottle: Eduard Buchner and the Growth of Biochemical Knowledge. Valencia, Spain: Publicacions de la Universitat de València.
14. Palmer G. "Chapter 3: The History of Glycolysis: An Example of a Linear Metabolic Pathway.". Bios 302 (PDF). Archived from the original (PDF) on 18 November 2017.
15. "Otto Meyerhof - Biographical". www.nobelprize.org. Retrieved 2016-02-23.
16. Kresge N, Simoni RD, Hill RL (January 2005). "Otto Fritz Meyerhof and the elucidation of the glycolytic pathway". The Journal of Biological Chemistry. 280 (4): e3. doi: 10.1016/S0021-9258(20)76366-0 . PMID   15665335.
17. "Embden, Gustav – Dictionary definition of Embden, Gustav | Encyclopedia.com: FREE online dictionary". www.encyclopedia.com. Retrieved 2016-02-23.
18. Reeves RE, South DJ, Blytt HJ, Warren LG (December 1974). "Pyrophosphate:D-fructose 6-phosphate 1-phosphotransferase. A new enzyme with the glycolytic function of 6-phosphofructokinase". The Journal of Biological Chemistry. 249 (24): 7737–7741. doi: 10.1016/S0021-9258(19)42029-2 . PMID   4372217.
19. Selig M, Xavier KB, Santos H, Schönheit P (April 1997). "Comparative analysis of Embden-Meyerhof and Entner-Doudoroff glycolytic pathways in hyperthermophilic archaea and the bacterium Thermotoga". Archives of Microbiology. 167 (4): 217–232. Bibcode:1997ArMic.167..217S. doi:10.1007/BF03356097. PMID   9075622. S2CID   19489719.
20. Garrett RH, Grisham CM (2012). Biochemistry (5th ed.). Cengage Learning. ISBN   978-1-133-10629-6.
21. Berg JM, Tymoczko JL, Stryer L (2007). Biochemistry (6th ed.). New York: Freeman. p. 622. ISBN   978-0-7167-8724-2.
22. Garrett R, Grisham CM (2005). Biochemistry (3rd ed.). Belmont, CA: Thomson Brooks/Cole. p. 584. ISBN   978-0-534-49033-1.
23. Shimizu K, Matsuoka Y (March 2019). "Regulation of glycolytic flux and overflow metabolism depending on the source of energy generation for energy demand". Biotechnology Advances. 37 (2): 284–305. doi:10.1016/j.biotechadv.2018.12.007. PMID   30576718. S2CID   58591361.
24. Chubukov V, Gerosa L, Kochanowski K, Sauer U (May 2014). "Coordination of microbial metabolism". Nature Reviews. Microbiology. 12 (5): 327–340. doi:10.1038/nrmicro3238. PMID   24658329. S2CID   28413431.
25. Hochachka PW (1999). "Cross-Species Studies of Glycolytic Function". In Roach RC, Wagner PD, Hackett PH (eds.). Hypoxia. Advances in Experimental Medicine and Biology. Vol. 474. Boston, MA: Springer US. pp. 219–229. doi:10.1007/978-1-4615-4711-2_18. ISBN   978-1-4613-7134-2. PMID   10635004.
26. Lemaigre FP, Rousseau GG (October 1994). "Transcriptional control of genes that regulate glycolysis and gluconeogenesis in adult liver". The Biochemical Journal. 303 (1): 1–14. doi:10.1042/bj3030001. PMC   1137548 . PMID   7945228.
27. Bian X, Jiang H, Meng Y, Li YP, Fang J, Lu Z (March 2022). "Regulation of gene expression by glycolytic and gluconeogenic enzymes". Trends in Cell Biology. 32 (9): 786–799. doi:10.1016/j.tcb.2022.02.003. PMID   35300892. S2CID   247459973.
28. Gerosa L, Sauer U (August 2011). "Regulation and control of metabolic fluxes in microbes". Current Opinion in Biotechnology. 22 (4): 566–575. doi:10.1016/j.copbio.2011.04.016. PMID   21600757.
29. Chowdhury S, Hepper S, Lodi MK, Saier MH, Uetz P (April 2021). "The Protein Interactome of Glycolysis in Escherichia coli". Proteomes. 9 (2): 16. doi: 10.3390/proteomes9020016 . PMC   8167557 . PMID   33917325.
30. Rodionova IA, Zhang Z, Mehla J, Goodacre N, Babu M, Emili A, et al. (August 2017). "The phosphocarrier protein HPr of the bacterial phosphotransferase system globally regulates energy metabolism by directly interacting with multiple enzymes in Escherichia coli". The Journal of Biological Chemistry. 292 (34): 14250–14257. doi: 10.1074/jbc.M117.795294 . PMC   5572926 . PMID   28634232.
31. Pisithkul T, Patel NM, Amador-Noguez D (April 2015). "Post-translational modifications as key regulators of bacterial metabolic fluxes". Current Opinion in Microbiology. 24: 29–37. doi:10.1016/j.mib.2014.12.006. PMID   25597444.
32. Koeslag JH, Saunders PT, Terblanche E (June 2003). "A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex". The Journal of Physiology. 549 (Pt 2) (published 2003): 333–346. doi:10.1113/jphysiol.2002.037895. PMC   2342944 . PMID   12717005.
33. Stryer L (1995). "Glycolysis.". Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 483–508. ISBN   0-7167-2009-4.
34. Stryer L (1995). Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. p. 773. ISBN   0-7167-2009-4.
35. Voet D, Voet JG, Pratt CW (2006). Fundamentals of Biochemistry (2nd ed.). John Wiley and Sons, Inc. pp.  547, 556. ISBN   978-0-471-21495-3.
36. Beis I, Newsholme EA (October 1975). "The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates". The Biochemical Journal. 152 (1): 23–32. doi:10.1042/bj1520023. PMC   1172435 . PMID   1212224.
37. Voet D, Voet JG (2004). Biochemistry (3rd ed.). New York: John Wiley & Sons, Inc.
38. Lackie J (2010). TIGAR. Oxford Reference Online: Oxford University Press. ISBN   978-0-19-954935-1.
39. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. (July 2006). "TIGAR, a p53-inducible regulator of glycolysis and apoptosis". Cell. 126 (1): 107–120. doi: 10.1016/j.cell.2006.05.036 . PMID   16839880. S2CID   15006256.
40. "TIGAR TP53 induced glycolysis regulatory phosphatase [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2018-05-17.
41. Carbonell J, Felíu JE, Marco R, Sols A (August 1973). "Pyruvate kinase. Classes of regulatory isoenzymes in mammalian tissues". European Journal of Biochemistry. 37 (1): 148–156. doi:10.1111/j.1432-1033.1973.tb02969.x. hdl: 10261/78345 . PMID   4729424.
42. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A (June 2000). "The allosteric regulation of pyruvate kinase". The Journal of Biological Chemistry. 275 (24): 18145–18152. doi: 10.1074/jbc.m001870200 . PMID   10751408.
43. Israelsen WJ, Vander Heiden MG (July 2015). "Pyruvate kinase: Function, regulation and role in cancer". Seminars in Cell & Developmental Biology. 43: 43–51. doi:10.1016/j.semcdb.2015.08.004. PMC   4662905 . PMID   26277545.
44. Engström L (1978). "The regulation of liver pyruvate kinase by phosphorylation--dephosphorylation". Current Topics in Cellular Regulation. 13. Elsevier: 28–51. doi:10.1016/b978-0-12-152813-3.50006-9. ISBN   978-0-12-152813-3. PMID   208818.
45. Stryer L (1995). "Oxidative phosphorylation.". Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 537–549. ISBN   0-7167-2009-4.
46. Stryer L (1995). "Fatty acid metabolism.". Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 603–628. ISBN   0-7167-2009-4.
47. Stryer L (1995). "Biosynthesis of membrane lipids and steroids.". Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 691–707. ISBN   0-7167-2009-4.
48. Stryer L (1995). "Citric acid cycle.". Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 509–527, 569–579, 614–616, 638–641, 732–735, 739–748, 770–773. ISBN   0-7167-2009-4.
49. Judge A, Dodd MS (2020-10-08). "Metabolism". Essays in Biochemistry. 64 (4): 607–647. doi:10.1042/EBC20190041. ISSN   0071-1365. PMC   7545035 . PMID   32830223.
50. Stryer L (1995). Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 559–565, 574–576, 614–623. ISBN   0-7167-2009-4.
51. Guo X, Li H, Xu H, Woo S, Dong H, Lu F, et al. (2012-08-01). "Glycolysis in the control of blood glucose homeostasis". Acta Pharmaceutica Sinica B. 2 (4): 358–367. doi: 10.1016/j.apsb.2012.06.002 . ISSN   2211-3835.
52. Wehbe Z, Behringer S, Alatibi K, Watkins D, Rosenblatt D, Spiekerkoetter U, et al. (2019-11-01). "The emerging role of the mitochondrial fatty-acid synthase (mtFASII) in the regulation of energy metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1864 (11): 1629–1643. doi:10.1016/j.bbalip.2019.07.012. ISSN   1388-1981. PMID   31376476.
53. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, et al. (2014). "Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question". Oncoscience. 1 (12): 777–802. doi:10.18632/oncoscience.109. PMC   4303887 . PMID   25621294.
54. Alfarouk KO, Shayoub ME, Muddathir AK, Elhassan GO, Bashir AH (July 2011). "Evolution of Tumor Metabolism might Reflect Carcinogenesis as a Reverse Evolution process (Dismantling of Multicellularity)". Cancers. 3 (3): 3002–3017. doi: 10.3390/cancers3033002 . PMC   3759183 . PMID   24310356.
55. Nelson DL, Cox MM (2005). Lehninger principles of biochemistry (4th ed.). New York: W.H. Freeman. ISBN   978-0-7167-4339-2.
56. Gold J (October 2011). "What is Cancer?". Archived from the original on May 19, 2018. Retrieved September 8, 2012.
57. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP (October 2000). "Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies". Journal of Cancer Research and Clinical Oncology. 126 (10): 549–59. doi:10.1007/pl00008465. PMID   11043392. S2CID   2725555.
58. "PET Scan: PET Scan Info Reveals ..." Retrieved December 5, 2005.
59. Schwartz L, Seyfried T, Alfarouk KO, Da Veiga Moreira J, Fais S (April 2017). "Out of Warburg effect: An effective cancer treatment targeting the tumor specific metabolism and dysregulated pH". Seminars in Cancer Biology. 43: 134–138. doi:10.1016/j.semcancer.2017.01.005. PMID   28122260.
60. Schwartz L, Supuran CT, Alfarouk KO (2017). "The Warburg Effect and the Hallmarks of Cancer". Anti-Cancer Agents in Medicinal Chemistry. 17 (2): 164–170. doi:10.2174/1871520616666161031143301. PMID   27804847.
61. Maroon J, Bost J, Amos A, Zuccoli G (August 2013). "Restricted calorie ketogenic diet for the treatment of glioblastoma multiforme". Journal of Child Neurology. 28 (8): 1002–1008. doi:10.1177/0883073813488670. PMID   23670248. S2CID   1994087.
62. Bonafe CF, Bispo JA, de Jesus MB (January 2018). "The polygonal model: A simple representation of biomolecules as a tool for teaching metabolism". Biochemistry and Molecular Biology Education. 46 (1): 66–75. doi: 10.1002/bmb.21093 . PMID   29131491. S2CID   31317102.

External links

• A Detailed Glycolysis Animation provided by IUBMB (Adobe Flash Required)
• The Glycolytic enzymes in Glycolysis at RCSB PDB
• Glycolytic cycle with animations at wdv.com
• Metabolism, Cellular Respiration and Photosynthesis - The Virtual Library of Biochemistry, Molecular Biology and Cell Biology
• The chemical logic behind glycolysis at ufp.pt
• Expasy biochemical pathways poster at ExPASy
• MedicalMnemonics.com: 317 5468
• metpath: Interactive representation of glycolysis